Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

By sjmartinez • April 27, 2024

Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177. PMID: 38666907; PMCID: PMC11049225.

Tags: biomarkers, CDKN2A, Hematology/Oncology, KRAS, pancreatic cancer, PDAC, Publications, SMAD4, targeted therapy, TP53, tumor markers, tumor suppressor genes

Related Posts

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma

Galanina N, Iqbal M, Tomassetti S, Nousome D, Tin A, Gillespie CP, Youngberg H, Miller P, Malhotra M, Widden H, Rodriguez A, Liu MC, Narkhede[...]

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara[...]